Faculty profile

Natasha Leighl

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Toronto

Natasha Leighl

Assistant Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
10 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

3,517

Citations

124

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.
JTO clinical and research reports · 2026
Bridging the gap in lung cancer: A comprehensive global strategy for change.
European journal of cancer (Oxford, England : 1990) · 2026
Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.
JTO clinical and research reports · 2025

All 51 publications

Latest funding

Improving Access and Wellbeing of Patients with Lung Cancer: A Randomized Controlled Trial of a Lay Navigation Program
CIHR · 2025 · Co-investigator
$753,526
Unconventional Innate-like T cells and Innate Lymphoid Cells as a Foundation for Novel Immunotherapeutic and Adoptive Cell Therapy Strategies in Metastatic Non-Small Cell Lung Cancer
CIHR · 2023 · Co-investigator
$1,000,000
Symptom screening and early palliative care in patients with advanced cancer: a randomized trial
CIHR · 2016 · Co-investigator
$1,002,150

All 5 grants and awards

51 publications.

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.

Munarriz BJ, Khan S, Hueniken K, Tam S, Patel D, Zhan L, Brown C, Eng L, Sacher A, Bradbury P, Leighl N, Liu G, Shepherd FA

JTO clinical and research reports20261 citationsOpen Access

DOI: 10.1016/j.jtocrr.2025.100918 PMID: 41479841

Bridging the gap in lung cancer: A comprehensive global strategy for change.

Syrigos KN, Bussell ME, Al-Shamsi HO, Khorshid O, Herbst RS, Agelaki S, Leighl N, Hirsch F, Wakelee H

European journal of cancer (Oxford, England : 1990)2026

DOI: 10.1016/j.ejca.2025.116069 PMID: 41421886

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.

Alghabban A, Corke L, Katzberg H, Bril V, Barnett-Tapia C, Mason W, Alothman R, Albiruni Ryan AR, Hogg D, Sridhar S, Dhani N, Spreafico A, Eng L, Sacher A, Bradbury P, Liu G, Leighl N, Shepherd FA

JTO clinical and research reports20255 citationsOpen Access

DOI: 10.1016/j.jtocrr.2024.100772 PMID: 40242666

Impact of the COVID-19 Pandemic on Diagnosis and Multidisciplinary Treatment of NSCLC in Ontario, Canada.

Perdrizet K, Le LW, Lau A, Tai X, Rabey MR, Law JH, Maziak D, Leighl N

JTO clinical and research reports2025Senior author

DOI: 10.1016/j.jtocrr.2025.100869 PMID: 40832568

Screening for lung cancer with computed tomography: protocol for systematic reviews for the Canadian Task Force on Preventive Health Care

Pillay J, Rahman S, Klarenbach S, Reynolds DL, Tessier LA, Thériault G, Persaud N, Finley C, Leighl N, McInnes MDF

Systematic Reviews20249 citationsOpen Access

DOI: 10.1186/s13643-024-02506-3 PMID: W4392881422

Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective

Breadner D, Hwang DM, Husereau D, Cheema P, Doucette S, Ellis PM, Kassam S, Leighl N, Maziak DE, Selvarajah S

Current Oncology20245 citationsOpen Access

DOI: 10.3390/curroncol31100449

Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.

Malapelle U, Leighl N, Addeo A, Hershkovitz D, Hochmair MJ, Khorshid O, Länger F, de Marinis F, Peled N, Sheffield BS, Smit EF, Viteri S, Wolf J, Venturini F, O'Hara RM, Rolfo C

British journal of cancer2024

DOI: 10.1038/s41416-024-02709-4 PMID: 38750115

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A

The Lancet2023120 citations

DOI: 10.1016/s0140-6736(23)01613-6

Influence of anterior tumor location on survival after resection of lung cancer invading the thoracic inlet (Pancoast tumors).

Tsitsias T, Yasufuku K, Pierre A, Leighl N, Cho J, Waddell TK, Darling G, Cypel M, Donahoe L, Yeung J, Keshavjee S, de Perrot M

The Journal of thoracic and cardiovascular surgery20239 citationsOpen Access

DOI: 10.1016/j.jtcvs.2022.10.033 PMID: 36481062

Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.

Castro PP, de Perrot M, Chua YC, Bezjak A, Leighl N, Darling G, Pierre A, Yasufuku K, Cypel M, Waddell T, Donahoe L, Yeung J, Keshavjee S

The Journal of thoracic and cardiovascular surgery20227 citationsOpen Access

DOI: 10.1016/j.jtcvs.2022.02.015 PMID: 35331553

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Natasha Leighl

Research

Latest papers

Latest funding

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC.

Bridging the gap in lung cancer: A comprehensive global strategy for change.

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors.

Impact of the COVID-19 Pandemic on Diagnosis and Multidisciplinary Treatment of NSCLC in Ontario, Canada.

Screening for lung cancer with computed tomography: protocol for systematic reviews for the Canadian Task Force on Preventive Health Care

Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective

Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Influence of anterior tumor location on survival after resection of lung cancer invading the thoracic inlet (Pancoast tumors).

Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.

Improving Access and Wellbeing of Patients with Lung Cancer: A Randomized Controlled Trial of a Lay Navigation Program

Unconventional Innate-like T cells and Innate Lymphoid Cells as a Foundation for Novel Immunotherapeutic and Adoptive Cell Therapy Strategies in Metastatic Non-Small Cell Lung Cancer

Symptom screening and early palliative care in patients with advanced cancer: a randomized trial

A systematic review of factors influencing older adults' decision to accept or refuse cancer treatment proposed by their physician

Influence of Beliefs about Symptoms on Symptom Intensity, Distress and Patient's Participation in Self-Management Behaviors in Lung Cancer

Frequent collaborators

Ming Tsao

Ming-Sound Tsao

Andrea Bezjak

Geoffrey Liu

Marc de Perrot

Penelope Bradbury

Adrian Sacher

Rosalyn Juergens

John Cho

Lesley Seymour

John Goffin

Thomas Waddell

Andrew Hope

Anthony Brade

Anna Spreafico

Shaf Keshavjee

Amit Oza

Dongsheng Tu

Ronald Burkes

David Hwang

Paul Wheatley-Price

Normand Blais

Rima Al-awar

Laura Donahoe

Karen Mcrae

David Goldstein

Ian Tannock

Levon Halabelian

Masoud Vedadi

Kévin Jao

Milan Patel

Jean-Pierre Ayoub

Warren Mason

Andrew Pierre

Stephen Lewis